AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11073017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 8882920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (CBT)
Number of subjects: 56
Study 8882920 — intervention group
Group type: COMPARATOR
Intervention: Non-focussed intervention (NFI)
Number of subjects: 56
Study 8398526 — intervention group
Group type: EXPERIMENTAL
Intervention: lumbar extradural analgesia using 0.5% bupivacaine 1 mg kg‐1 plus morphine 50 micrograms kg‐1
Number of subjects: 30
Study 8398526 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 100 micrograms kg‐1 i.m.
Number of subjects: 30
Study 8398526 — intervention group
Group type: EXPERIMENTAL
Intervention: subpubic block using 0.5% bupivacaine 0.5 mg kg‐1 for each side
Number of subjects: 30
Study 3768764 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500 micrograms X kg‐1 X min‐1 for four minutes, then 300 micrograms X kg‐1 X min‐1 for 8 minutes)
Number of subjects: 30
Study 3768764 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30
Study 3768764 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 29675767 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with autism spectrum disorder (ASD)
Number of subjects: 123
Study 27589605 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning
Number of subjects: 74
Study 27589605 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based teaching
Number of subjects: 74
Study 27589605 — intervention group
Group type: COMPARATOR
Intervention: Traditional methodology
Number of subjects: 74
Study 24991030 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive repetitive transorbital alternating current stimulation (rtACS; 10 days, 40 minutes daily; n = 7)
Number of subjects: 28
Study 24991030 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 8)
Number of subjects: 28
Study 24991030 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with partial optic nerve damage
Number of subjects: 28
Study 22910840 — intervention group
Group type: EXPERIMENTAL
Intervention: Second line therapy (platinum combination, n = 313, 24.5%)
Number of subjects: 1620
Study 22910840 — intervention group
Group type: EXPERIMENTAL
Intervention: Third line therapy (topotecan, n = 118, 23.6%)
Number of subjects: 1620
Study 22910840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth line therapy
Number of subjects: 1620
Study 22910840 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth line therapy
Number of subjects: 1620
Study 20523215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 61
Study 20523215 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve stimulator
Number of subjects: 61
Study 20523215 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between peripheral nerve stimulator and acceleromyography
Number of subjects: 61
Study 18677171 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-min exercise training sessions
Number of subjects: 134
Study 18677171 — intervention group
Group type: COMPARATOR
Intervention: 60-min exercise training sessions
Number of subjects: 134
Study 15976235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 36
Study 15976235 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 100 mg
Number of subjects: 36
Study 15976235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12612947 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO plus KAs plus LPD (group I)
Number of subjects: 186
Study 12612947 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO plus LPD (group II)
Number of subjects: 186
Study 12612947 — intervention group
Group type: COMPARATOR
Intervention: LPD (group III)
Number of subjects: 186
Study 10491228 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with spine fractures
Number of subjects: 642
Study 10491228 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women without spine fractures
Number of subjects: 642
Study 10491228 — intervention group
Group type: COMPARATOR
Intervention: Matched by aBMD
Number of subjects: 642
Study 10491228 — intervention group
Group type: COMPARATOR
Intervention: Matched by vertebral volume
Number of subjects: 642
Study 9085622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg IV after 500 ml of enteral nutrition
Number of subjects: 24
Study 9085622 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg IV after 500 ml of enteral nutrition
Number of subjects: 24
Study 1716935 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-89
Number of subjects: 32
Study 1716935 — intervention group
Group type: COMPARATOR
Intervention: Stable strontium (placebo)
Number of subjects: 32
Study 6354113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 119
Study 6354113 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin-neomycin-cefazolin
Number of subjects: 119
Study 30329102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco advertisement liking
Number of subjects: 9109
Study 30329102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational attainment
Number of subjects: 9109
Study 30329102 — intervention group
Group type: EXPERIMENTAL
Intervention: Living below the poverty level
Number of subjects: 9109
Study 30150397 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventure game
Number of subjects: 320
Study 30150397 — intervention group
Group type: EXPERIMENTAL
Intervention: Puzzle game
Number of subjects: 320
Study 30150397 — intervention group
Group type: COMPARATOR
Intervention: Text-based education
Number of subjects: 320
Study 30150397 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 320
Study 26864124 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (not specified dosage or duration)
Number of subjects: 0
Study 26864124 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment intensity (insulin, statins, oral antihypertensive drugs)
Number of subjects: 0
Study 24499445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints on the disease-affected meridian (DAM)
Number of subjects: 404
Study 24499445 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at acupoints on the non-affected meridian (NAM)
Number of subjects: 404
Study 24499445 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-acupoint (NA)
Number of subjects: 404
Study 24499445 — intervention group
Group type: COMPARATOR
Intervention: No intervention (wait-listed group)
Number of subjects: 404
Study 21849640 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-positive patients
Number of subjects: 314
Study 21849640 — intervention group
Group type: COMPARATOR
Intervention: CS-negative patients
Number of subjects: 314
Study 19827461 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD), 5.5 +/- 0.3 g/d of L-arginine
Number of subjects: 9
Study 19827461 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet 2 (same as CD but including an oral supplement of 15 g/d), 20.5 +/- 0.3 g/d of L-arginine
Number of subjects: 9
Study 17341512 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocervical flexor training
Number of subjects: 68
Study 17341512 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength training of the cervical flexor muscles
Number of subjects: 68
Study 17341512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 15155305 — intervention group
Group type: EXPERIMENTAL
Intervention: DBRCT.af computer search strategy
Number of subjects: 0
Study 15155305 — intervention group
Group type: COMPARATOR
Intervention: Optimally Sensitive Search Strategy
Number of subjects: 0
Study 15155305 — intervention group
Group type: COMPARATOR
Intervention: RCT.pt standard MEDLINE strategy
Number of subjects: 0
Study 15155305 — intervention group
Group type: COMPARATOR
Intervention: DBRCT.af computer algorithm
Number of subjects: 0
Study 11847826 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual breast pump (MP)
Number of subjects: 60
Study 11847826 — intervention group
Group type: COMPARATOR
Intervention: Mini-electric breast pump (MEP)
Number of subjects: 60
Study 9492093 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fraction of L-tryptophan in plasma
Number of subjects: 0
Study 9492093 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan and serotonin synthesis
Number of subjects: 0
Study 9492093 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fraction of plasma L-tryptophan
Number of subjects: 0
Study 8830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-R (100mg)
Number of subjects: 7
Study 8830646 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50mg)
Number of subjects: 7
Study 8830646 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 7
Study 3266541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium metabisulfite solutions (0.5, 1, 10, 25, 50 mg, 100 mg, 200 mg)
Number of subjects: 44
Study 3266541 — intervention group
Group type: COMPARATOR
Intervention: Lactose-placebo
Number of subjects: 44
Study 29682865 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (n=64)
Number of subjects: 127
Study 29682865 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation (n=63)
Number of subjects: 127
Study 27465318 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic recreation program (TR-EF) delivered through electronically based games during 200 1-hour sessions (5/week) for 40 weeks
Number of subjects: 37
Study 27465318 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 37
Study 26092062 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teriparatide
Number of subjects: 542
Study 24019415 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe cerebral palsy (Mod/Sev CP)
Number of subjects: 115
Study 24019415 — intervention group
Group type: COMPARATOR
Intervention: No cerebral palsy (No CP)
Number of subjects: 115
Study 24019415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy feeds
Number of subjects: 115
Study 22132861 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy (training session, information, opinion leader, reminders, audit, and feedback)
Number of subjects: 296
Study 22132861 — intervention group
Group type: COMPARATOR
Intervention: Usual diffusion (control group)
Number of subjects: 296
Study 22132861 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 296
Study 19487264 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 173
Study 19487264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 17029118 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 96
Study 17029118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 96
Study 17029118 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 96
Study 12617709 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 50 to 59 years
Number of subjects: 2041
Study 12617709 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 80 years and older
Number of subjects: 2041
Study 12617709 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants 70 years and older
Number of subjects: 2041
Study 11025425 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT) prior to radical prostatectomy
Number of subjects: 0
Study 11025425 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHT) prior to radiation therapy
Number of subjects: 0
Study 11025425 — intervention group
Group type: COMPARATOR
Intervention: Radiation only
Number of subjects: 0
Study 11025425 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study 9105988 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 40 ppm
Number of subjects: 6
Study 9105988 — intervention group
Group type: COMPARATOR
Intervention: Control condition (ventilated with 70% oxygen and 30% nitrogen)
Number of subjects: 6
Study 8444251 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortifier A (bovine proteins, peptides, and amino acids)
Number of subjects: 24
Study 8444251 — intervention group
Group type: COMPARATOR
Intervention: Fortifier B (freeze-dried skimmed human milk and minerals)
Number of subjects: 24
Study 3770017 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 3770017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 30
Study 3770017 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and diuretic
Number of subjects: 30
Study 3770017 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol and diuretic
Number of subjects: 30
Study 30957240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (INT)
Number of subjects: 746
Study 30957240 — intervention group
Group type: COMPARATOR
Intervention: Adherent patients (ADH)
Number of subjects: 746
Study 29531173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (always alone)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (never alone)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (alone for rest)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group (alone for BP measurement)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: COMPARATOR
Intervention: Standard group (always alone)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: COMPARATOR
Intervention: Standard group (never alone)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: COMPARATOR
Intervention: Standard group (alone for rest)
Number of subjects: 4082
Study 29531173 — intervention group
Group type: COMPARATOR
Intervention: Standard group (alone for BP measurement)
Number of subjects: 4082
Study 26914585 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (H1N1 strain)
Number of subjects: 133
Study 26914585 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (H3N2 strain)
Number of subjects: 133
Study 26914585 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (B strain)
Number of subjects: 133
Study 23733907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology only at baseline
Number of subjects: 1100
Study 23733907 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat cytology after negative baseline cytology
Number of subjects: 1100
Study 23733907 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HPV16/18 genotyping
Number of subjects: 1100
Study 23733907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HPV16/18 genotyping at baseline and repeat cytology testing
Number of subjects: 1100
Study 22640372 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteo-cise intervention (multi-modal exercise program with high velocity progressive resistance training, moderate impact weight-bearing exercise, and high challenging balance exercises performed three times weekly)
Number of subjects: 0
Study 22640372 — intervention group
Group type: COMPARATOR
Intervention: Self-management control group
Number of subjects: 0
Study 20119672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative periarticular multimodal drug injections (PMDI)
Number of subjects: 55
Study 20119672 — intervention group
Group type: COMPARATOR
Intervention: No-PMDI (control group)
Number of subjects: 55
Study 17653518 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE sizing as the sole tool for selecting device size in group 2 (10 patients)
Number of subjects: 40
Study 17653518 — intervention group
Group type: COMPARATOR
Intervention: Balloon sizing and TTE sizing in group 1 (30 patients)
Number of subjects: 40
Study 17653518 — intervention group
Group type: EXPERIMENTAL
Intervention: TTE sizing
Number of subjects: 40
Study 16039414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa extract (Cr 99)
Number of subjects: 122
Study 16039414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 12095018 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 47
Study 12095018 — intervention group
Group type: COMPARATOR
Intervention: Meperidine 50 mg
Number of subjects: 47
Study 12095018 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (rescue medication)
Number of subjects: 47
Study 9474073 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 0
Study 9474073 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected controls
Number of subjects: 0
Study 8919987 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.50 mg/ml + ketorolac 1.50 mg/ml (Group 2)
Number of subjects: 180
Study 8919987 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.75 mg/ml + ketorolac 0.75 mg/ml (Group 1)
Number of subjects: 180
Study 8919987 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.25 mg/ml + ketorolac 1.50 mg/ml (Group 3)
Number of subjects: 180
Study 2136826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms, 200 micrograms, and 800 micrograms)
Number of subjects: 9
Study 2136826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2136826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 9
Study 400713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin (iv)
Number of subjects: 39
Study 400713 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular insulin (im)
Number of subjects: 39
Study 400713 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (sc)
Number of subjects: 39
Study 400713 — intervention group
Group type: COMPARATOR
Intervention: Lean patients
Number of subjects: 39
Study 400713 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 39
Study 31607720 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey applied to the wound after tooth extraction
Number of subjects: 51
Study 31607720 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS) applied to the wound after tooth extraction
Number of subjects: 51
Study 28693596 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation intervention (standard CPG implementation plus facilitation)
Number of subjects: 4
Study 28693596 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation of clinical practice guidelines (CPGs)
Number of subjects: 4
Study 25909619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with laryngeal mask
Number of subjects: 65
Study 23702058 — intervention group
Group type: EXPERIMENTAL
Intervention: Supination-Flexion (SF) technique
Number of subjects: 150
Study 23702058 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpronation (HP) technique
Number of subjects: 150
Study 23702058 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 150
Study 21357180 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-meditation (shared or cross-breathing)
Number of subjects: 26
Study 19641488 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram or Nortriptyline
Number of subjects: 796
Study 19641488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 796
Study 18694136 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-interruptive alert within electronic medical record prompting lab orders with new prescriptions
Number of subjects: 0
Study 18694136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no non-interruptive alert)
Number of subjects: 0
Study 16821203 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (transsphenoidal surgery)
Number of subjects: 28
Study 16821203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment (Sandostatin LAR, 20 mg im, monthly)
Number of subjects: 28
Study 16821203 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 28
Study 11843524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valves (aortic)
Number of subjects: 0
Study 11843524 — intervention group
Group type: COMPARATOR
Intervention: Tissue valves (aortic)
Number of subjects: 0
Study 11843524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical mitral valves
Number of subjects: 0
Study 11843524 — intervention group
Group type: COMPARATOR
Intervention: Mitral tissue valves
Number of subjects: 0
Study 11843524 — intervention group
Group type: COMPARATOR
Intervention: Tissue valves (general)
Number of subjects: 0
Study 11843524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical valves (general)
Number of subjects: 0
Study 10350382 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of meropenem: 2 g iv loading dose followed by 3 g continuous infusion over 24 h
Number of subjects: 15
Study 10350382 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration (IA) of meropenem: 2 g iv every 8 h
Number of subjects: 15
Study 8596317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days)
Number of subjects: 1506
Study 8596317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin (Fragmin)
Number of subjects: 1506
Study 1959860 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucagon therapy (30 U insulin and 3 mg glucagon in 250 ml 5% dextrose over 12 hr each day for 3 wk)
Number of subjects: 86
Study 1959860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical regime to insulin and glucagon)
Number of subjects: 86
Study 1959860 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glucagon therapy
Number of subjects: 86
Study 1959860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 7337944 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate (DMP)
Number of subjects: 172
Study 7337944 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone succinate (MPS)
Number of subjects: 172
Study 7337944 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 172